Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.21.2
Revenue (Tables)
6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues From Licensing Agreements and Strategic Partnerships
The Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
  Three Months Ended June 30, Six Months Ended June 30,
  2021 2020 2021 2020
Seagen $ 338  $ 8,512  $ 704  $ 8,960 
AstraZeneca 2,202  2,334  16,702  5,045 
Servier 745  400  1,512  10,502 
Total Revenue $ 3,285  $ 11,246  $ 18,918  $ 24,507 
Schedule of Potential Milestone Payments
Under the Company’s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):
  Research, Development, Regulatory & Commercial Milestones Sales Milestones
AstraZeneca $ 1,096  $ 4,275 
Servier 239  214 
Seagen 754  450 
Boston Pharmaceuticals 88  265 
Genentech 834  600 
Total potential milestone payments $ 3,011  $ 5,804